enGene Reports Interim Results from NMIBC Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy ENGN?
Source: Yahoo Finance
- Efficacy Data Update: In the ongoing LEGEND Phase 2 trial, 54% of the 125 high-risk non-muscle invasive bladder cancer patients achieved a complete response (CR) at any time, with a 43% CR rate at six months, indicating the therapy's effectiveness and potential market prospects.
- Low Progression Rate: The trial reported a low progression rate to muscle-invasive or higher disease at only 3.2%, suggesting that patients remain eligible for other bladder-sparing therapies, enhancing the treatment's appeal.
- Good Safety Profile: 55% of patients experienced treatment-related adverse events (TRAEs), predominantly mild (Grade 1 and 2), with only 2.4% of patients experiencing treatment interruptions or discontinuations, demonstrating the therapy's favorable tolerability.
- FDA Engagement Plans: enGene plans to further engage with the FDA in preparation for a potential Biologics License Application (BLA) and will provide updates in the second half of 2026, reflecting the company's confidence and strategic positioning for future market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENGN
Wall Street analysts forecast ENGN stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.720
Low
10.00
Averages
23.88
High
33.00
Current: 1.720
Low
10.00
Averages
23.88
High
33.00
About ENGN
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into enGene Therapeutics Investor Claims
- Clinical Trial Results Disclosure: On May 7, 2026, enGene announced that in its LEGEND trial using detalimogene voraplasmid for high-risk bladder cancer patients, the complete response rate was 54% at any time and 43% at six months, but the 12-month duration of response was only 25%, indicating efficacy below expectations and potentially impacting investor confidence.
- Investor Loss Investigation: Following a sharp decline in enGene's stock price due to unfavorable results, Johnson Fistel is investigating whether the company violated federal securities laws, which may lead to claims for investor losses, reflecting concerns over corporate governance and transparency.
- Poor Patient Assessment Results: Among 32 patients assessed recently, the complete response rate dropped to 39% at any time and 32% at six months, significantly lower than previously reported results, which could undermine investor confidence in the company's future prospects.
- Law Firm Involvement: Johnson Fistel is a nationally recognized shareholder rights law firm focused on representing investors in securities class actions, ranked among the Top 10 Plaintiff Law Firms in 2024, demonstrating its strength in advocating for investor rights.
See More
enGene Reports Interim Results from NMIBC Clinical Trial
- Efficacy Data Update: In the ongoing LEGEND Phase 2 trial, 54% of the 125 high-risk non-muscle invasive bladder cancer patients achieved a complete response (CR) at any time, with a 43% CR rate at six months, indicating the therapy's effectiveness and potential market prospects.
- Low Progression Rate: The trial reported a low progression rate to muscle-invasive or higher disease at only 3.2%, suggesting that patients remain eligible for other bladder-sparing therapies, enhancing the treatment's appeal.
- Good Safety Profile: 55% of patients experienced treatment-related adverse events (TRAEs), predominantly mild (Grade 1 and 2), with only 2.4% of patients experiencing treatment interruptions or discontinuations, demonstrating the therapy's favorable tolerability.
- FDA Engagement Plans: enGene plans to further engage with the FDA in preparation for a potential Biologics License Application (BLA) and will provide updates in the second half of 2026, reflecting the company's confidence and strategic positioning for future market opportunities.
See More
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
ENGENE HOLDINGS INC.: OPPENHEIMER LOWERS TARGET PRICE FROM $33 TO $30
Company Overview: Engene Holdings Inc. is a company involved in various business activities, including investments and holdings.
Target Price Adjustment: Oppenheimer has reduced the target price for Engene Holdings from $33 to $30.
See More
enGene Holdings Q1 Financial Highlights
- Earnings Performance: enGene Holdings reported a Q1 GAAP EPS of $0.44, indicating stable profitability despite competitive market pressures.
- Cash Position: As of January 31, 2026, the company held $312.5 million in cash, cash equivalents, and marketable securities, providing ample funding for future investments and operations.
- Operating Expense Increase: Operating expenses for Q1 2026 totaled $31.2 million, a 17.3% increase from $26.6 million in 2025, reflecting ongoing investments in R&D and market expansion.
- Positive Market Reaction: enGene Holdings saw a 14% surge in stock price on Friday, indicating investor optimism regarding the company's future prospects, particularly with major catalysts on the horizon.
See More
Investigation into enGene Therapeutics Investor Claims
- Clinical Trial Results Disclosure: On May 7, 2026, enGene announced that in its LEGEND trial using detalimogene voraplasmid for high-risk bladder cancer patients, the complete response rate was 54% at any time and 43% at six months, but the 12-month duration of response was only 25%, indicating efficacy below expectations and potentially impacting investor confidence.
- Investor Loss Investigation: Following a sharp decline in enGene's stock price due to unfavorable results, Johnson Fistel is investigating whether the company violated federal securities laws, which may lead to claims for investor losses, reflecting concerns over corporate governance and transparency.
- Poor Patient Assessment Results: Among 32 patients assessed recently, the complete response rate dropped to 39% at any time and 32% at six months, significantly lower than previously reported results, which could undermine investor confidence in the company's future prospects.
- Law Firm Involvement: Johnson Fistel is a nationally recognized shareholder rights law firm focused on representing investors in securities class actions, ranked among the Top 10 Plaintiff Law Firms in 2024, demonstrating its strength in advocating for investor rights.
See More
enGene Reports Interim Results from NMIBC Clinical Trial
- Efficacy Data Update: In the ongoing LEGEND Phase 2 trial, 54% of the 125 high-risk non-muscle invasive bladder cancer patients achieved a complete response (CR) at any time, with a 43% CR rate at six months, indicating the therapy's effectiveness and potential market prospects.
- Low Progression Rate: The trial reported a low progression rate to muscle-invasive or higher disease at only 3.2%, suggesting that patients remain eligible for other bladder-sparing therapies, enhancing the treatment's appeal.
- Good Safety Profile: 55% of patients experienced treatment-related adverse events (TRAEs), predominantly mild (Grade 1 and 2), with only 2.4% of patients experiencing treatment interruptions or discontinuations, demonstrating the therapy's favorable tolerability.
- FDA Engagement Plans: enGene plans to further engage with the FDA in preparation for a potential Biologics License Application (BLA) and will provide updates in the second half of 2026, reflecting the company's confidence and strategic positioning for future market opportunities.
See More
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
ENGENE HOLDINGS INC.: OPPENHEIMER LOWERS TARGET PRICE FROM $33 TO $30
Company Overview: Engene Holdings Inc. is a company involved in various business activities, including investments and holdings.
Target Price Adjustment: Oppenheimer has reduced the target price for Engene Holdings from $33 to $30.
See More
enGene Holdings Q1 Financial Highlights
- Earnings Performance: enGene Holdings reported a Q1 GAAP EPS of $0.44, indicating stable profitability despite competitive market pressures.
- Cash Position: As of January 31, 2026, the company held $312.5 million in cash, cash equivalents, and marketable securities, providing ample funding for future investments and operations.
- Operating Expense Increase: Operating expenses for Q1 2026 totaled $31.2 million, a 17.3% increase from $26.6 million in 2025, reflecting ongoing investments in R&D and market expansion.
- Positive Market Reaction: enGene Holdings saw a 14% surge in stock price on Friday, indicating investor optimism regarding the company's future prospects, particularly with major catalysts on the horizon.
See More
